Overview
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2024-05-01
2024-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ra Pharmaceuticals
Criteria
Inclusion Criteria:- Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study
Exclusion Criteria:
- With the exception of a prior zilucoplan trial, participation in another concurrent
clinical trial involving an experimental therapeutic intervention (participation in
observational studies and/or registry studies is permitted)